These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Proteomics: addressing the challenges of multiple myeloma. Ge F; Tao S; Bi L; Zhang Z; Zhang X Acta Biochim Biophys Sin (Shanghai); 2011 Feb; 43(2):89-95. PubMed ID: 21212069 [TBL] [Abstract][Full Text] [Related]
5. Recombinant antibodies for the generation of antibody arrays. Borrebaeck CA; Wingren C Methods Mol Biol; 2011; 785():247-62. PubMed ID: 21901605 [TBL] [Abstract][Full Text] [Related]
6. The promise of bone cancer proteomics. Byrum S; Montgomery CO; Nicholas RW; Suva LJ Ann N Y Acad Sci; 2010 Mar; 1192():222-9. PubMed ID: 20392240 [TBL] [Abstract][Full Text] [Related]
7. Quantitative proteomic analysis of tumor reversion in multiple myeloma cells. Ge F; Zhang L; Tao SC; Kitazato K; Zhang ZP; Zhang XE; Bi LJ J Proteome Res; 2011 Feb; 10(2):845-55. PubMed ID: 21080727 [TBL] [Abstract][Full Text] [Related]
8. Application of 2D-DIGE in cancer proteomics toward personalized medicine. Kondo T; Hirohashi S Methods Mol Biol; 2009; 577():135-54. PubMed ID: 19718514 [TBL] [Abstract][Full Text] [Related]
9. Dithiothreitol-based protein equalisation in the context of multiple myeloma: Enhancing proteomic analysis and therapeutic insights. Domingos IF; Carvalho LB; Lodeiro C; Gerivaz R; Prag G; Micaglio E; Muchtar E; Santos HM; Capelo JL Talanta; 2024 Nov; 279():126589. PubMed ID: 39116730 [TBL] [Abstract][Full Text] [Related]
10. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Postma MJ; Boersma C; Vandijck D; Vegter S; Le HH; Annemans L Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):367-9. PubMed ID: 21831013 [No Abstract] [Full Text] [Related]
11. Personalized implant therapy: new perspectives in bone remodeling assessment. Razzouk S; Teixeira C N Y State Dent J; 2010; 76(4):50-2. PubMed ID: 20863042 [TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of multiple myeloma: current status and future perspectives. Ge F; Bi LJ; Tao SC; Xu XD; Zhang ZP; Kitazato K; Zhang XE Proteomics Clin Appl; 2011 Feb; 5(1-2):30-7. PubMed ID: 21280235 [TBL] [Abstract][Full Text] [Related]
13. Translational proteomics: what can you do for true patients? Belda-Iniesta C; de Castro J; Perona R J Proteome Res; 2011 Jan; 10(1):101-4. PubMed ID: 20977278 [TBL] [Abstract][Full Text] [Related]
15. Personalized medicine: a paradigm for a sustainable pharmaceutical industry? Chackalamannil S; Desai MC Curr Opin Drug Discov Devel; 2009 Jul; 12(4):443-5. PubMed ID: 19562640 [TBL] [Abstract][Full Text] [Related]
16. Approaching MALDI molecular imaging for clinical proteomic research: current state and fields of application. Rauser S; Deininger SO; Suckau D; Höfler H; Walch A Expert Rev Proteomics; 2010 Dec; 7(6):927-41. PubMed ID: 21142893 [TBL] [Abstract][Full Text] [Related]
17. A piece in the puzzle of personalized medicine. Kroemer HK; Meyer zu Schwabedissen HE Clin Pharmacol Ther; 2010 Jan; 87(1):19-20. PubMed ID: 20019696 [TBL] [Abstract][Full Text] [Related]
18. Use of formalin-fixed and paraffin-embedded tissues for diagnosis and therapy in routine clinical settings. Berg D; Malinowsky K; Reischauer B; Wolff C; Becker KF Methods Mol Biol; 2011; 785():109-22. PubMed ID: 21901596 [TBL] [Abstract][Full Text] [Related]
19. Next generation personalized animals as an enabling technology in personalized vaccinology. Poland GA; Mirochnitchenko O Vaccine; 2013 Jan; 31(5):725-7. PubMed ID: 23337595 [No Abstract] [Full Text] [Related]
20. Personalized medicine in oncology: tailoring the right drug to the right patient. Jiang Y; Wang M Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]